Objective: To explore the clinical significance of tumor associated material (TAM) and β2-microglobulin (β2-MG) in the diagnosis and evaluation of chemotherapeutic efifcacy in patients with non-Hodgkin’s lymphoma (NHL). Methods:A total of 161 patients with NHL and another 37 examined healthy people were selected to detect their serum TAM and β2-MG levels and analyze the relationship between TAM and β2-MG with NHL progression and prognosis. Results:Serum TAM and β2-MG levels in NHL patients were higher than in healthy people (P<0.05), and were evidently higher in NHL patients with concurrent bone marrow inifltration than in those without bone marrow inifltration (P<0.05), which had no relevant association in ages and genders (P>0.05), but were lower in patients with indolent lymphoma than in those with invasive and high-invasive lymphoma (P<0.05). Additionally, there were signiifcant differences in TAM and β2-MG levels between patients in phasesⅠ~Ⅱ andⅢ~Ⅳ (P>0.05), which decreased evidently after treatment than treatment before (P<0.05). Conclusion:The levels of serum TAM and β2-MG expression in patients with NHL have a certain guiding signiifcance for clinical staging, pathological malignant severity and tumor invasive severity, and detection of TAM and β2-MG has a certain value in diagnosing the therapeutic responses to NHL, able to be an effective index for the diagnosis and efifcacy evaluation in patients with NHL.